Navigation Links
Dendreon Reports Third Quarter 2010 Financial Results
Date:11/3/2010

SEATTLE, Nov. 3, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2010. Revenue for the third quarter ended September 30, 2010 was $20.2 million compared to $25,000 for the quarter ended September 30, 2009. Revenue for the nine months ended September 30, 2010 was $23.1 million compared to $80,000 for the nine months ended September 30, 2009.  

Revenue from sales of PROVENGE® (sipuleucel-T) steadily increased month over month from $5.2 million in July, to $7.2 million in August and $7.8 million in September. In addition, revenue for October was approximately $9.5 million.

“We’re pleased with the progress we have made in the first six months of the launch of PROVENGE,” said Mitchell H. Gold, M.D., president and chief executive officer. “We look forward to making PROVENGE available to the many patients who may benefit from it and who have had very few appealing treatment options prior to the FDA approval of PROVENGE.”

Dendreon's total operating expenses for the third quarter of 2010 were $87.7 million compared to $25.8 million in the third quarter of 2009. Dendreon’s total operating expenses for the nine months ended September 30, 2010 were $213.7 million compared to $63.7 million for the same period in 2009. Total operating expenses for the three and nine months ended September 30, 2010 include a charge of $13.3 million for the settlement of litigation. The net loss for the quarter ended September 30, 2010 was $79.3 million, or $0.56 per share, which includes a $0.09 charge for the litigation settlement, compared to $45.6 million, or $0.40 per share for the quarter ended September 30, 2009, which included a non-cash charge associated with the revaluation of warrants of $19.4 million or $0.17 per share. The net loss for the nine months ended S
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
2. Dendreon Statement on CMS National Coverage Analysis
3. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
4. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
5. Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
6. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
7. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
8. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data Solutions ... new website design . The main website, along with ... the company,s new services and content relevant to the ... new streamlined design, viewers can now better understand how ... care practices and create a more visible platform about ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ –  Royal ... AEX: PHIA) today announced its ... of Cardiology (ESC) Congress 2014 , where ... of its cardiology solutions serving clinicians and patients ... and diagnosis, to treatment, recovery ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2PMDS Announces New Website 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 3Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 4Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 5
... 21, 2007 - Antigenics Inc.,(NASDAQ: AGEN) today ... 3 investigational therapeutic cancer vaccine,Oncophage(R) (vitespen). The ... data collection, showed that in a substantial,subset ... risk for disease,recurrence, Oncophage demonstrated a clinically ...
... FDA for long-term,maintenance treatment of COPD bronchoconstriction; ... lung function,comparable to dry powder formoterol, enhanced ... -- , NAPA, CA (May 20, 2007) ... the American Thoracic Society (ATS),demonstrate that Perforomist™ ...
Cached Medicine Technology:Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 2Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 3Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
(Date:8/29/2014)... August 29, 2014 According to new research ... Not Peer Pressure, Key to Prescription Drug Misuse Among Young ... focus for 18-29 year olds when it comes to prescription ... for this age group the real problem which influences misuse ... associations and recreational use of them to have fun with ...
(Date:8/29/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Glass microfiber including its ... explores global and China’s top manufacturers of Glass ... and market share etc. , The report further ...
(Date:8/29/2014)... Mirada, CA (PRWEB) August 29, 2014 ... which will give patients the convenience of visiting ... with Healthpointe doctors through telemedicine. , Healthpointe doctors are ... calls (or audio). If necessary, the doctor can even ... assessed the patient’s condition, he or she can prescribe ...
(Date:8/29/2014)... 2014 Healthpointe is pleased to ... Therapy students via Clinical Rotations. Physical ... shadowing Healthpointe providers and specialists throughout their daily ... clinical experience and learn professional preparation. ... insight into several patient care techniques and expand ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Healthpointe ... J. Chuang, has joined their practice. Dr. Chuang garners ... and specializes in minimally-invasive arthroscopic and reconstructive treatments of ... care for patients with general and sports-related orthopedic needs. ... in the medical field. As an Orange County native, ...
Breaking Medicine News(10 mins):Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If you,re ... recall due to salmonella contamination has probably made you refrain from ... now some time has passed, and you,re starting to crave an ... languishing in your fridge or are you inviting a bout of ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- ... caloric overindulgence can be easily worked off at the gym, ... a month,s worth of unhealthy living changes physiology, making piled-on ... [over-eating] can have later long-term effects," said study co-author Dr. ...
... in seven patients experience more pain, physical and emotional problems ... quarter have less vitality. Those are the key findings of ... by the British Journal of Surgery . ... men with an average age of 54, who had undergone ...
... TUESDAY, Aug. 24 (HealthDay News) -- A new study finds ... the glucose-lowering diabetes drugs Avandia and Actos are about the ... studies that found that the risk was elevated for Avandia ... in line with some other previous studies, further muddying the ...
... room waiting times could be cut by over one third ... a new approach to the triage process of sorting ... in the International Journal of Six Sigma and Competitive ... University in Zarqa, Jordan and colleagues have turned to a ...
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay ... the herpes virus should not worry that their use ... than 1 percent of women develop herpes simplex during ... during pregnancy of antiviral drugs such as acyclovir (Zovirax), ...
Cached Medicine News:Health News:Are The Eggs in Your Fridge Safe to Eat? 2Health News:Are The Eggs in Your Fridge Safe to Eat? 3Health News:Are The Eggs in Your Fridge Safe to Eat? 4Health News:Short-Term Overeating Could Make Long-Term Weight Loss Tougher 2Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 3Health News:Engineering shorter wait times in the ER 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 3
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Nucleus chopper. For bimanual nucleus division....
Phaco chopper, short (0.75 mm) pointed "quick chop" tip....
Medicine Products: